{"id":66473,"recorded_at":"2026-10-26T14:37:40.623780Z","observed_at":"2026-10-26T14:37:40.623722Z","subject_kind":"source_record","subject":"x402_bazaar:https://api.healthtravel-api.workers.dev/api/health/fda-purple-book","kind":"listing","method":"baseline/1","body":{"endpoints":[["x402","https://api.healthtravel-api.workers.dev/api/health/fda-purple-book"]],"name":"SiteCheck Health & Travel","owner_address":"0xb8491f953e6860d3b5840b73c60883ff099ceafa","raw":{"accepts":[{"amount":"2000","asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"maxTimeoutSeconds":300,"network":"eip155:8453","payTo":"0xb8491F953e6860D3b5840b73c60883Ff099ceAfA","scheme":"exact"},{"amount":"2000","asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"BFK9TLC3edb13K6v4YyH3DwPb5DSUpkWvb7XnqCL9b4F"},"maxTimeoutSeconds":300,"network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","payTo":"J8vnmBx4pS1X7UUBTfz1yWBKiw69Dj2yRGRHDaXBRdhR","scheme":"exact"},{"amount":"2000","asset":"0x3600000000000000000000000000000000000000","extra":{"name":"USDC","version":"2"},"maxTimeoutSeconds":300,"network":"eip155:5042","payTo":"0xa4751fCAa83c9669cfe507bb6807507729839be3","scheme":"exact"},{"amount":"2000","asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"maxTimeoutSeconds":300,"network":"eip155:137","payTo":"0xb8491F953e6860D3b5840b73c60883Ff099ceAfA","scheme":"exact"},{"amount":"2000","asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"maxTimeoutSeconds":300,"network":"eip155:42161","payTo":"0xb8491F953e6860D3b5840b73c60883Ff099ceAfA","scheme":"exact"},{"amount":"2000","asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"maxTimeoutSeconds":300,"network":"eip155:143","payTo":"0xb8491F953e6860D3b5840b73c60883Ff099ceAfA","scheme":"exact"},{"amount":"2000","asset":"0x79A02482A880bCE3F13e09Da970dC34db4CD24d1","extra":{"name":"USDC","version":"2"},"maxTimeoutSeconds":300,"network":"eip155:480","payTo":"0xb8491F953e6860D3b5840b73c60883Ff099ceAfA","scheme":"exact"},{"amount":"2000","asset":"0x0b2C639c533813f4Aa9D7837CAf62653d097Ff85","extra":{"name":"USD Coin","version":"2"},"maxTimeoutSeconds":300,"network":"eip155:10","payTo":"0xb8491F953e6860D3b5840b73c60883Ff099ceAfA","scheme":"exact"},{"amount":"2000","asset":"0xcebA9300f2b948710d2653dD7B07f33A8B32118C","extra":{"name":"USDC","version":"2"},"maxTimeoutSeconds":300,"network":"eip155:42220","payTo":"0xb8491F953e6860D3b5840b73c60883Ff099ceAfA","scheme":"exact"},{"amount":"0.002","asset":"524C555344000000000000000000000000000000","extra":{"areFeesSponsored":false,"invoiceId":"a4a2a285-79d6-4891-8845-e92624468d70","issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","sourceTag":804681468},"maxTimeoutSeconds":300,"network":"xrpl:0","payTo":"rDxNZCDfLxUzeMWGGwsY3sjQT8eoZCf8UJ","scheme":"exact"},{"amount":"1534","asset":"XRP","extra":{"areFeesSponsored":false,"invoiceId":"c0168a46-21a8-4065-9aed-33dfe2c6ac2f","sourceTag":804681468},"maxTimeoutSeconds":300,"network":"xrpl:0","payTo":"rDxNZCDfLxUzeMWGGwsY3sjQT8eoZCf8UJ","scheme":"exact"}],"description":"FDA Purple Book licensed biological products matching a name (brand or proper name, e.g. adalimumab): applicant, BLA number, license type (351(a) originator, 351(k) biosimilar or interchangeable), strength, dosage form, route, marketing status, approval date, reference product and exclusivity expiry dates, plus the products newly approved or updated this month. From FDA's monthly Purple Book data download.","extensions":{"bazaar":{"info":{"input":{"method":"GET","queryParams":{"limit":"5","name":"adalimumab"},"type":"http"},"output":{"example":{"changedThisMonth":[{"applicant":"Emerge Bioscience Pte. Ltd.","approvalDate":"December 17, 2021","blaNumber":"761216","center":"CDER","change":"U","dosageForm":"Injection","exclusivityExpires":null,"firstInterchangeableExclusivityExpires":null,"licenseType":"351(k) Interchangeable","marketingStatus":"Rx","orphanExclusivityExpires":null,"presentation":"Pre-Filled Syringe","properName":"adalimumab-aqvh","proprietaryName":"Yusimry","referenceProduct":"Humira","referenceProductExclusivityExpires":null,"route":"Subcutaneous","strength":"40MG/0.8ML"},{"applicant":"Emerge Bioscience Pte. Ltd.","approvalDate":"February 27, 2023","blaNumber":"761216","center":"CDER","change":"U","dosageForm":"Injection","exclusivityExpires":null,"firstInterchangeableExclusivityExpires":null,"licenseType":"351(k) Interchangeable","marketingStatus":"Rx","orphanExclusivityExpires":null,"presentation":"Autoinjector","properName":"adalimumab-aqvh","proprietaryName":"Yusimry","referenceProduct":"Humira","referenceProductExclusivityExpires":null,"route":"Subcutaneous","strength":"40MG/0.8ML"}],"checkedAt":"2026-10-23T09:36:23.320Z","count":5,"products":[{"applicant":"Pfizer Inc.","approvalDate":"November 15, 2019","blaNumber":"761118","center":"CDER","change":null,"dosageForm":"Injection","exclusivityExpires":null,"firstInterchangeableExclusivityExpires":null,"licenseType":"351(k) Interchangeable","marketingStatus":"Rx","orphanExclusivityExpires":null,"presentation":"Autoinjector","properName":"adalimumab-afzb","proprietaryName":"Abrilada","referenceProduct":"Humira","referenceProductExclusivityExpires":null,"route":"Subcutaneous","strength":"40MG/0.8ML"},{"applicant":"Pfizer Inc.","approvalDate":"November 15, 2019","blaNumber":"761118","center":"CDER","change":null,"dosageForm":"Injection","exclusivityExpires":null,"firstInterchangeableExclusivityExpires":null,"licenseType":"351(k) Interchangeable","marketingStatus":"Rx","orphanExclusivityExpires":null,"presentation":"Pre-Filled Syringe","properName":"adalimumab-afzb","proprietaryName":"Abrilada","referenceProduct":"Humira","referenceProductExclusivityExpires":null,"route":"Subcutaneous","strength":"40MG/0.8ML"}],"query":"adalimumab","report":"Purple Book Monthly Historical Data Changes Report - September 2026","source":"https://www.accessdata.fda.gov/drugsatfda_docs/PurpleBook/2026/purplebook-search-September-data-download.csv","total":68},"type":"json"}},"schema":{"$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"input":{"additionalProperties":false,"properties":{"method":{"enum":["GET"],"type":"string"},"queryParams":{"properties":{"limit":{"description":"Products to return, 1 to 100 (default 25)","type":"string"},"name":{"description":"Brand or proper (nonproprietary) name, or BLA number (required)","type":"string"}},"required":["name"],"type":"object"},"type":{"const":"http","type":"string"}},"required":["type","method"],"type":"object"},"output":{"properties":{"example":{"type":"object"},"type":{"type":"string"}},"required":["type"],"type":"object"}},"required":["input"],"type":"object"}}},"lastUpdated":"2026-10-23T20:25:55.804Z","quality":{"l30DaysTotalCalls":2,"l30DaysUniquePayers":2,"lastCalledAt":"2026-10-23T20:25:55.661Z"},"resource":"https://api.healthtravel-api.workers.dev/api/health/fda-purple-book","serviceName":"SiteCheck Health & Travel","tags":["health","fda","purple","book"],"type":"http","x402Version":2},"source":"x402_bazaar","summary":"FDA Purple Book licensed biological products matching a name (brand or proper name, e.g. adalimumab): applicant, BLA number, license type (351(a) originator, 351(k) biosimilar or interchangeable), strength, dosage form, route, marketing status, approval date, reference product and exclusivity expiry dates, plus the products newly approved or updated this month. From FDA's monthly Purple Book data download."},"body_sha256":"d48b9b2ac0aac9e9184e5f4ab58ffd353e94b5250c6117d9adbb1904ae85ea09","prev_id":null,"leaf":"0x4cb18909790ef9e7ae0e9fb9ed2ae680974b93780cef318c3abf449da4ba388d","leaf_text":"{\"body\":\"d48b9b2ac0aac9e9184e5f4ab58ffd353e94b5250c6117d9adbb1904ae85ea09\",\"id\":66473,\"kind\":\"listing\",\"method\":\"baseline/1\",\"observed_us\":1793025460623722,\"prev\":null,\"subject\":\"x402_bazaar:https://api.healthtravel-api.workers.dev/api/health/fda-purple-book\",\"subject_kind\":\"source_record\"}","day":null,"proof":[]}